Trial Profile
A retrospective multicenter cohort study investigating short-term and long-term efficacy of Golimumab as first, second or third anti-TNF agent in patients with moderate-to-severe ulcerative colitis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jul 2018
Price :
$35
*
At a glance
- Drugs Golimumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- 24 Jul 2018 New trial record